VCRE

9.4055.10%
HJ

Hans J. G. C. P. Schikan

Independent & Non-Executive Vice Chairman

Mr. Hans J. G. C. P. Schikan, Pharm.D., serves as an Advisor at Forty51 Advisors AG. He is Senior Advisor at Odlander, Fredrikson & Co. AB. He is a Director at VectivBio Holding AG since June 2019. Mr. Schikan serves as Independent Vice Chairman of the Board at Pharvaris N.V. Mr. Schikan co-founded Pharvaris B.V. and serves as its Non-Executive Director since August 28, 2019. Mr. Schikan serves as a Senior Advisor at HealthCap. Mr. Schikan serves as Independent Director at Vicore Pharma Holding AB (publ) since August 2018 and serves as Independent Chairman since May 7, 2024. He serves as Independent Non-Executive Chairman at Microbiotica Limited since February 24, 2021. Mr. Schikan served as the Chief Executive Officer of BioMarin Nederland B.V. from January 2009 to January 2015 and its Member of Management Board until January 2015. He was responsible for all BioMarin Nederland B.V.'s corporate functions and the overall management and strategic direction. He served at Genzyme, where he was responsible for the global marketing and strategy development of the genetic disease portfolio of orphan medicinal products, which includes the first treatment for Pompe disease. Prior to Genzyme, he spent several years at Organon, both at corporate level and in country operations which included assignments in Asia and Europe. Mr. Schikan has development, commercial and leadership experience in the biopharmaceutical and biotechnology sector. Mr. Schikan serves as Chairman of the Board at InteRNA Technologies, Swanbridge Capital. Mr. Schikan served as Chairman of the Board at Asceneuron SA until January 2019. He has been the Chairman of the Board at Complix NV since July 29, 2015. He has been Non-Executive Director of TherAchon SAS since February 15, 2017. He has been a Member of Supervisory Board at BioMarin Nederland B.V., since January 2015. He had been a Director of Wilson Therapeutics AB since June 30, 2015. From January 2017 through May 2019, he served as a member of the board of directors at Therachon Holding AG. He was an Independent Director of Swedish Orphan Biovitrum AB (Sobi) since April 28, 2011. In addition, he serves as a Member of the Advisory Board of BioScience Park Leiden and as an Independent Member of the Supervisory Board of BioMarin Nederland B.V. and as a Board member of Top Team Dutch Top Sector Life Sciences & Health. Currently, he is also on the Board of several biotechnology companies in the Netherlands, Belgium, Sweden and Switzerland. Previously, he served as Chairman of Nefarma and as a Member of the Biotechnology Industry Organization's Emerging Companies Section Governing Board. He serves as Director at VectivBio. Mr. Schikan was previously at Genzyme, most recently serving as VP for Global Marketing and Strategic Development of Genzyme's product portfolio for rare genetic diseases. He also served as a Member of the Advisory Board of ALS Investment Fund. He is Adviser of Khondrion (Netherlands) and Confo Therapeutics (Belgium). He served as Director at Hansa Medical AB from June 02, 2015, to May 29, 2018. He is also a Pharmacist. Mr. Schikan holds a Pharm.D., degree from the University of Utrecht University, The Netherlands.

Positions